Clinical Trial: Chemoprevention With Folic Acid

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: 3389 Colorectal Adenoma: Chemoprevention With Folic Acid

Brief Summary: Colorectal neoplasia is the second most common cancer in the United States and other Western countries with about 140,000 newly diagnosed cases per year in the United States with a mortality rate of about 40%. The identification of a specific natural or synthetic compound with the ability to reverse or suppress the process of colon carcinogenesis would have profound implication in the development of colorectal adenomas and their subsequent transformation to colon cancer. Furthermore, the establishment of a correlative relationship between biomarkers of cell proliferation, differentiation, apoptosis and adenoma recurrence would provide pivotal data required to elucidate cell signaling mechanisms in future colon cancer chemoprevention trials.

Detailed Summary:
Sponsor: VA Office of Research and Development

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: VA Office of Research and Development

Dates:
Date Received: July 3, 2001
Date Started: October 1998
Date Completion: September 2003
Last Updated: January 20, 2009
Last Verified: December 2004